Although genetic factors are very effective in kidney stones, we must try to delay this problem with environmental factors as well
As retatrutide remains an investigational medicine without full regulatory approval in the UK, it is important that any suspected side effects are reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app, in addition to informing your trial team
Prefer to leave your details
WHO and EMA Warnings About Semaglutide and NAION In June 2025, the World Health Organization alerted healthcare professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with semaglutide medications, including Ozempic, Rybelsus, and Wegovy
Retatrutide helps activate receptors in the brain that regulate appetite
We offer a comprehensive approach to aesthetics and concierge care